Baraldi PG - Search Results

1

Recent improvements in the development of A(2B) adenosine receptor agonists.

Baraldi PG, Tabrizi MA, Fruttarolo F, Romagnoli R, Preti D. Baraldi PG, et al. Purinergic Signal. 2008 Dec;4(4):287-303. doi: 10.1007/s11302-008-9097-z. Epub 2008 Apr 29. Purinergic Signal. 2008. PMID: 18443746 Free PMC article.

2

Recent developments in the field of A2A and A3 adenosine receptor antagonists.

Baraldi PG, Tabrizi MA, Bovero A, Avitabile B, Preti D, Fruttarolo F, Romagnoli R, Varani K, Borea PA. Baraldi PG, et al. Eur J Med Chem. 2003 Apr;38(4):367-82. doi: 10.1016/s0223-5234(03)00042-4. Eur J Med Chem. 2003. PMID: 12750024

3

Synthesis and biological evaluation of novel N6-[4-(substituted)sulfonamidophenylcarbamoyl]adenosine-5'-uronamides as A3 adenosine receptor agonists.

Baraldi PG, Fruttarolo F, Tabrizi MA, Romagnoli R, Preti D, Bovero A, Pineda de Las Infantas MJ, Moorman A, Varani K, Borea PA. Baraldi PG, et al. J Med Chem. 2004 Oct 21;47(22):5535-40. doi: 10.1021/jm0408161. J Med Chem. 2004. PMID: 15481989

4

Ligands for A2B adenosine receptor subtype.

Baraldi PG, Romagnoli R, Preti D, Fruttarolo F, Carrion MD, Tabrizi MA. Baraldi PG, et al. Curr Med Chem. 2006;13(28):3467-82. doi: 10.2174/092986706779010306. Curr Med Chem. 2006. PMID: 17168717 Review.

5

Synthesis and biological evaluation of novel 1-deoxy-1-[6-[((hetero)arylcarbonyl)hydrazino]- 9H-purin-9-yl]-N-ethyl-beta-D-ribofuranuronamide derivatives as useful templates for the development of A2B adenosine receptor agonists.

Baraldi PG, Preti D, Tabrizi MA, Fruttarolo F, Romagnoli R, Carrion MD, Cara LC, Moorman AR, Varani K, Borea PA. Baraldi PG, et al. J Med Chem. 2007 Jan 25;50(2):374-80. doi: 10.1021/jm061170a. J Med Chem. 2007. PMID: 17228880

6

N(6)-[(hetero)aryl/(cyclo)alkyl-carbamoyl-methoxy-phenyl]-(2-chloro)-5'-N-ethylcarboxamido-adenosines: the first example of adenosine-related structures with potent agonist activity at the human A(2B) adenosine receptor.

Baraldi PG, Preti D, Tabrizi MA, Fruttarolo F, Saponaro G, Baraldi S, Romagnoli R, Moorman AR, Gessi S, Varani K, Borea PA. Baraldi PG, et al. Among authors: baraldi s. Bioorg Med Chem. 2007 Apr 1;15(7):2514-27. doi: 10.1016/j.bmc.2007.01.055. Epub 2007 Feb 2. Bioorg Med Chem. 2007. PMID: 17306548

7

1,3-Dipropyl-8-(1-phenylacetamide-1H-pyrazol-3-yl)-xanthine derivatives as highly potent and selective human A(2B) adenosine receptor antagonists.

Tabrizi MA, Baraldi PG, Preti D, Romagnoli R, Saponaro G, Baraldi S, Moorman AR, Zaid AN, Varani K, Borea PA. Tabrizi MA, et al. Among authors: baraldi s, baraldi pg. Bioorg Med Chem. 2008 Mar 1;16(5):2419-30. doi: 10.1016/j.bmc.2007.11.058. Epub 2007 Nov 28. Bioorg Med Chem. 2008. PMID: 18077171

8

Recent improvements in the development of A(2B) adenosine receptor agonists.

Baraldi PG, Tabrizi MA, Fruttarolo F, Romagnoli R, Preti D. Baraldi PG, et al. Purinergic Signal. 2009 Mar;5(1):3-19. doi: 10.1007/s11302-009-9140-8. Epub 2009 Jan 31. Purinergic Signal. 2009. PMID: 19184536 Free PMC article.

9

Novel 8-heterocyclyl xanthine derivatives in drug development - an update.

Baraldi PG, Fruttarolo F, Tabrizi MA, Romagnoli R, Preti D. Baraldi PG, et al. Expert Opin Drug Discov. 2007 Sep;2(9):1161-83. doi: 10.1517/17460441.2.9.1161. Expert Opin Drug Discov. 2007. PMID: 23496127

10

Pyrazolo-triazolo-pyrimidine derivatives as adenosine receptor antagonists: a possible template for adenosine receptor subtypes?

Baraldi PG, Cacciari B, Borean PA, Varanin K, Pastorin G, Da Ros T, Tabrizi MA, Fruttarolo F, Spalluto G. Baraldi PG, et al. Curr Pharm Des. 2002;8(26):2299-332. doi: 10.2174/1381612023392838. Curr Pharm Des. 2002. PMID: 12369947 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

247 results

Search Page